Pivekimab sunirine is a monoclonal antibody conjugated commercialized by ImmunoGen, with a leading Phase II program in Natural Killer Cell Lymphomas. According to Globaldata, it is involved in 3 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Pivekimab sunirine’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Pivekimab sunirine is expected to reach an annual total of $20 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Pivekimab sunirine Overview
IMGN-632 is under development for the treatment of CD123-positive hematologic malignancies include blastic plasmacytoid dendritic cell neoplasm, myeloproliferative disorders, acute lymphocytic leukemia, natural killer cell lymphomas, myelodysplastic syndrome, relapsed and refractory acute myeloid leukemia. It is administered through the intravenous route. The drug candidate is a conjugate of a humanized anti-CD123 antibody with a payload that alkylates DNA.
It was also under development for the treatment of chronic myelocytic leukemia (CML, chronic myeloid leukemia), chronic myelomonocytic leukemia (CMML).
ImmunoGen is a clinical-stage biotechnology company that focuses on the development of novel antibody-drug conjugates (ADCs) that facilitate targeted therapies for the treatment of cancer. Its pipeline product candidates include mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer; IMGN632 for AML, and pivekimab sunirine for blastic plasmacytoid dendritic cell neoplasm (BPDCN); IMGC936, the company’s product candidate for a range of solid tumors; and IMGN151, its next-generation anti-FRa candidate in the preclinical development stage. ImmunoGenorporates its proprietary product development ADC technology to enhance the anticancer activity of monoclonal antibodies. The company has direct operations in the US, Ireland, and the UK. ImmunoGen is headquartered in Waltham, Massachusetts, the US.
The company reported revenues of (US Dollars) US$108.8 million for the fiscal year ended December 2022 (FY2022), an increase of 55.7% over FY2021. The operating loss of the company was US$220.9 million in FY2022, compared to an operating loss of US$125.1 million in FY2021. The net loss of the company was US$222.9 million in FY2022, compared to a net loss of US$139.3 million in FY2021. The company reported revenues of US$113.4 million for the third quarter ended September 2023, an increase of 36.4% over the previous quarter.
For a complete picture of Pivekimab sunirine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.